Cross-specialty identification of the JAK1 inhibitor trial agent filgotinib as a potential therapy for alopecia areata
Br J Dermatol
.
2023 Feb 22;188(3):442-443.
doi: 10.1093/bjd/ljac103.
Authors
Nicole Fagan
1
,
Glen A Doherty
2
3
,
Nekma Meah
4
5
,
Rodney Sinclair
6
,
Dmitri Wall
7
8
Affiliations
1
St James's Hospital, Dublin, Ireland.
2
St. Vincent's University Hospital, Dublin, Ireland.
3
Department of Medicine, University College Dublin, Ireland.
4
St Helens and Knowsley Teaching Hospitals NHS Trust, St Helens, UK.
5
Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK.
6
Sinclair Dermatology, Melbourne, Australia.
7
Charles Institute of Dermatology, UCD School of Medicine, University College Dublin, Dublin, Ireland.
8
Hair Restoration Blackrock, Blackrock, Dublin, Ireland.
PMID:
36680304
DOI:
10.1093/bjd/ljac103
No abstract available
MeSH terms
Alopecia Areata*
Humans
Janus Kinase 1
Janus Kinase Inhibitors*
Pyridines
Substances
GLPG0634
Janus Kinase Inhibitors
Pyridines
JAK1 protein, human
Janus Kinase 1
Supplementary concepts
Diffuse alopecia